Harte Hanks (HHS)
(Delayed Data from NSDQ)
$7.45 USD
+0.06 (0.81%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.35 -0.10 (-1.34%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.45 USD
+0.06 (0.81%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.35 -0.10 (-1.34%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Zacks News
Recent Price Trend in Harte-Hanks (HHS) is Your Friend, Here's Why
by Zacks Equity Research
Harte-Hanks (HHS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Harte-Hanks (HHS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Harte-Hanks (HHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Advertising & Marketing Outlook Dull Amid Coronavirus Mayhem
by Shuvra Shankar Dey
Significant rise in digital media consumption should be able to somewhat offset the coronavirus crisis' unfavorable impact on the industry.
All You Need to Know About Harte-Hanks (HHS) Rating Upgrade to Strong Buy
by Zacks Equity Research
Harte-Hanks (HHS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
National CineMedia (NCMI) Jumps: Stock Rises 10.6%
by Zacks Equity Research
National CineMedia (NCMI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
4 Advertising & Marketing Stocks to Gain Amid Coronavirus Scare
by Zacks Equity Research
With strict lockdowns across the globe in the wake of coronavirus outbreak, people are spending more time indoor on various media platforms and streaming video services.
Harte-Hanks (HHS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harte-Hanks (HHS) delivered earnings and revenue surprises of -92.21% and 2.87%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Harte-Hanks (HHS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Harte-Hanks (HHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harte-Hanks (HHS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Harte-Hanks (HHS) delivered earnings and revenue surprises of 169.39% and 2.50%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Harte-Hanks (HHS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Harte-Hanks (HHS) delivered earnings and revenue surprises of -31.17% and -5.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Advertising and Marketing Outlook: Dismal Show Continues
by Zacks Equity Research
With the FBI examining buying practices in media, the industry continuous to grapple with tremendous pressure.
Harte-Hanks (HHS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Harte-Hanks (HHS) delivered earnings and revenue surprises of -74.60% and -12.41%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Weight Watchers, Johnson Outdoors, ChemoCentryx, Harte-Hanks and IEC
by Zacks Equity Research
Zacks.com featured highlights include: Weight Watchers, Johnson Outdoors, ChemoCentryx, Harte-Hanks and IEC
7 Stocks With Recent Price Strength to Enhance Your Returns
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Why MDC Partners (MDCA) Could Be Positioned for a Slump
by Zacks Equity Research
MDC Partners (MDCA) is one stock you should avoid as it has seen a significant price decline and is also seeing negative earnings estimate revisions.
Harte Hanks (HHS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Harte Hanks, Inc. (HHS).
Harte Hanks Amends Credit Facility to Improve Liquidity
by Zacks Equity Research
The modified credit agreement is likely to provide the means to undertake strategic investments to spur long-term growth of Harte Hanks, Inc. (HHS).
Harte Hanks Partners with Usermind to Enhance Portfolio
by Zacks Equity Research
Harte Hanks, Inc. (HHS), recently announced its collaboration with Usermind's Customer Engagement Hub, to provide customers consulting and data management solutions.